Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ5 | P48544 | 1/20 | 0.47 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | CTPS1 | P17812 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027736 | 0.88 | AURKA (0.49) | MAPTLMNAMEN1KMT2AHPGD | |
| SCHEMBL5027769 | 0.87 | TSHR (0.45) | MAPTLMNAMEN1KMT2ACCNE1 | |
| SCHEMBL5025190 | 0.85 | SMN1; SMN2 (0.42) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5026015 | 0.83 | CCNE1 (0.44) | MAPTMEN1KMT2AALDH1A1CCNE1 | |
| SCHEMBL5045081 | 0.78 | CCNE1 (0.42) | MAPTMEN1KMT2AALDH1A1CCNE1 | |
| SCHEMBL5025993 | 0.78 | SCD (0.45) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5025349 | 0.78 | L3MBTL1 (0.55) | KCNJ5KCNJ3MAPTCTPS1LMNA | |
| SCHEMBL5046778 | 0.77 | CCNE1 (0.45) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL27543447 | 0.74 | ALDH1A1 (0.51) | LMNAALDH1A1CCNE1CDK2CDK5 | |
| SCHEMBL5041435 | 0.71 | AURKA (0.53) | MAPTMEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407946-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| EP-1299381-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2002000649-A9 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| CN-1267431-C | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | CN | disclosed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | US | disclosed |
| EP-1575946-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| US-6919338-B2 | Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase | ASTRAZENECA AB (SE) | 2005-07-19 | — | — | US | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| CN-1496364-A | Substituted quinazoline derivatives and their use as inhibitors | — | 2004-05-12 | — | — | CN | disclosed |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1299381-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002000649-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058523-A1 | Quinazoline compounds | NDUFS5, ABL1, NDUFS7 | KCNJ5 558/4885KCNJ3 1084/4885MAPT 1301/4885 |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKB, AURKC | KCNJ5 1677/4885KCNJ3 1404/4885MAPT 1921/4885 |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKC, AURKB | KCNJ5 1647/4885KCNJ3 1490/4885MAPT 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.